I3 Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for I3 PHARMS, and what generic and branded alternatives to I3 PHARMS drugs are available?
I3 PHARMS has six approved drugs.
Summary for I3 Pharms
| US Patents: | 0 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 6 |
Drugs and US Patents for I3 Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I3 Pharms | CHLORZOXAZONE | chlorzoxazone | TABLET;ORAL | 212053-001 | Sep 14, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| I3 Pharms | RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 213517-001 | Apr 27, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| I3 Pharms | RAMELTEON | ramelteon | TABLET;ORAL | 212650-001 | Apr 10, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| I3 Pharms | ZAROXOLYN | metolazone | TABLET;ORAL | 017386-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| I3 Pharms | ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 215988-001 | Jan 17, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| I3 Pharms | RANOLAZINE | ranolazine | TABLET, EXTENDED RELEASE;ORAL | 213517-002 | Apr 27, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| I3 Pharms | ZAROXOLYN | metolazone | TABLET;ORAL | 017386-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
